Pacific Biosciences of California, Inc. (PACB)
After hours:
| Previous close | 1.9050 |
| Open | 2.0000 |
| Bid | 2.1200 x 4900 |
| Ask | 2.1500 x 3600 |
| Day's range | 1.9607 - 2.1800 |
| 52-week range | 1.1600 - 13.6700 |
| Volume | |
| Avg. volume | 10,047,885 |
| Market cap | 581.48M |
| Beta (5Y monthly) | 2.04 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.1400 |
| Earnings date | 07 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.33 |
ZacksPacific Biosciences of California (PACB) Ascends While Market Falls: Some Facts to Note
Pacific Biosciences of California (PACB) concluded the recent trading session at $1.88, signifying a +1.62% move from its prior day's close.
ZacksPacBio's (PACB) Revio System to Boost Novogene's German Lab
PacBio (PACB) announces that Novogene is set to use PACB's Revio long-read sequencing system to expand the capabilities of its new lab in Munich, Germany.
GlobeNewswireNovogene to Power Cancer, Rare Disease, and Environmental Research with PacBio Sequencing
Highly accurate long-read sequencing data will be used at Novogene’s new lab in Munich, supporting customers across a network of leading research institutionsMENLO PARK, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that Novogene is using its Revio long-read sequencing system to expand the capabilities of its new lab in Munich, Germany, serving customers across the European scientific co
